Filing Flows › 8-K events › Cyngn
Cyngn: departure or appointment of directors and officers
Form 8-K filed Oct 30, 2026 · items 3.01, 5.02
What the filing says
On October 26, 2026, Karen Macleod, a member of the Board and Chair of the Board’s Audit Committee, notified the Company of her decision not to stand for re-election as a director at the Company’s 2026 Annual Meeting of Stockholders to be held on November 3, 2026 (the “Annual Meeting”). Macleod will continue to serve a
Read the filing on SEC EDGAR →
What usually followsAcross 492 8-Ks reporting Item 3.01 (delisting notice or listing-rule failure) in our universe, the stock's median move the next session was 0.0% (typical size ±2.1%, up 46% of the time); over the following 21 sessions, −0.2%. Item 5.02: −0.1% next session across 39,174. Every item ranked →
What this kind of filing means
Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.
Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.
Cyngn at a glance
Cyngn, Q2 2026: revenue $144K (+328% year over year). The chart follows the revenue to costs, profit and cash.
Cyngn: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent delisting notices
- Barfresh Food Group Nov 6, 2026
- Fifth Era Acquisition Corp I Nov 6, 2026
- Tempest Therapeutics Nov 6, 2026
- Roku Nov 6, 2026
- Bowman Consulting Group Nov 6, 2026
- Knightscope Nov 6, 2026
- Curis Nov 6, 2026
- Intrusion Nov 5, 2026
- Karyopharm Therapeutics Nov 5, 2026
- Cognition Therapeutics Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.